On July 16, after a demonstration organized by relevant departments of China’s State Council’s joint prevention and control mechanism, the new crown virus inactivated vaccine developed by Beijing Institute of Biological Products of Sinopharm Group , was officially approved for emergency use in people aged 3-17.
At present, the vaccine has completed phase I/II clinical trials in Henan. The positive conversion rate of neutralizing antibody in people age 3-17 is 100%, safety after vaccination is good, and the main adverse reactions are fever and pain at the inoculation site , The severity was mainly grade 1, and no serious adverse reactions were noticed ; the incidence of adverse reactions gradually decreased with the increase in the number of inoculation doses.
On June 6, the immuno-bridging clinical trial of the new crown inactivated vaccine developed by the Beijing Institute of Biological Products of Sinopharm Group in the 3-17-year-old group was launched in Abu Dhabi, UAE, evaluating 900 people of different nationalities aged 3-17 . After the Sinopharm China Bio-New Crown Inactivated Vaccine obtained conditional marketing approval, it continued to carry out expanded clinical trials in the 3 to 17-year-old population . The safety and effectiveness data of more than 60,000 people passed expert demonstrations, and the vaccine was officially approved for emergency use in this age group.